Oscar Health, Inc. (OSCR) Stock Drops Despite Market Gains: Important Facts to Note

Oscar Health closed at $15.65, down 1.57% on the day and lagging broader benchmarks, though shares are up 16.9% over the past month versus the Finance sector’s 3.3% gain. The company is set to report earnings on Feb. 4, 2025, with consensus expecting a loss per share of $0.58 (a 12.1% improvement year-over-year) and revenue of $2.46 billion (a 71.9% year-over-year increase). Valuation shows a forward P/E of 20.8—well above the Insurance multi-line peer average of 9.7—while a PEG of 0.64 implies outsized growth expectations; Zacks currently assigns a Neutral (#3) rank and places the industry in the lower half (rank 142). The upcoming print and any analyst estimate revisions will be pivotal for assessing whether the recent top-line acceleration and improving EPS trajectory justify the premium valuation.

Analysis

Oscar Health closed at $15.65, down 1.57% on the latest trading day, underperforming the S&P 500's 0.88% advance while the Dow and Nasdaq rose 1.24% and 0.65% respectively. The stock has nevertheless gained 16.91% over the past month, materially outpacing the Finance sector's 3.25% and the S&P 500's 1.17%, which signals stock-specific momentum ahead of the company's upcoming report.

The company is slated to report earnings on February 4, 2025; consensus projects EPS of -$0.58 (a 12.12% YoY improvement) and revenue of $2.46 billion (a 71.91% YoY increase), indicating market expectations for significant top-line acceleration and gradual margin recovery. Consensus EPS estimates have been stagnant over the past 30 days, so the print and any guidance will be pivotal for catalyzing upward analyst revisions.

Oscar Health trades at a forward P/E of 20.78 versus its Insurance multi-line peer average of 9.74, implying a substantial premium, while a PEG of 0.64 compares favorably to the industry PEG of 1.05 and suggests the market is pricing above-average growth. Zacks assigns a Neutral (#3) rank and places the industry at rank 142 (bottom 44%); sentiment is mildly positive (0.25) with a modest market-impact score (0.3), so earnings beats or misses are likely to produce amplified moves.

Key Decisions for Investors

• Reduce position size or avoid initiating new large positions ahead of the February 4 earnings print to limit exposure to event-driven volatility
• If results beat consensus (revenue near or above $2.46 billion and EPS better than -$0.58) and analysts raise estimates, consider adding to positions given the low PEG of 0.64 that implies growth justifying a premium
• If the company misses revenue or EPS expectations or issues weak guidance, trim exposure or hedge, because the forward P/E of 20.78 is a sizable premium to the industry's 9.74 and could compress on negative news
• Monitor analyst estimate revisions and any change in the Zacks Rank immediately after the release, as the report indicates these revisions have historically driven near-term stock moves